Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma

Eur J Dermatol. 2021 Oct 1;31(5):655-657. doi: 10.1684/ejd.2021.4131.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bortezomib / therapeutic use
  • Dapsone / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Dexamethasone / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy*
  • Thalidomide / therapeutic use
  • Vasculitis, Leukocytoclastic, Cutaneous / complications*
  • Vasculitis, Leukocytoclastic, Cutaneous / drug therapy*
  • Vasculitis, Leukocytoclastic, Cutaneous / pathology

Substances

  • Antineoplastic Agents
  • Dermatologic Agents
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Dapsone

Supplementary concepts

  • Erythema elevatum diutinum